Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Market Access Impact: Rheumatoid Arthritis (EU5) 2018

Product Code:
s_596201185
Publication Date:
November 2018
Format:
PowerPoint
Price:
£4,515

What are the market access obstacles that are shaping the EU5 rheumatoid arthritis market and which brands are winning out?

  • How are market barriers affecting rheumatoid arthritis drug prescribing?
  • How do market barriers affect the market share of leading brands?
  • What specific market access barriers are challenging each brand?
  • Which brands gain and lose the most market share due to market barriers?

High cost, no formulary listing and stock availability are just some of the barriers that can negatively influence prescribing volumes and exert downward pressure on profitability. What market access barriers are influencing physicians’ therapy choices and how is this determining market share?

This and other key questions are answered in this insightful November 2018 analysis of 12 leading rheumatoid arthritis (RA) brands. Based on the results of an in-depth survey of 150 EU5-based rheumatologists, Market Access Impact (EU5): Rheumatoid Arthritis identifies the market access barriers that are shaping the competitive landscape for leading rheumatoid arthritis brands in the EU5 and provides clear pointers for management action.

Buy Now

Buy and Download this report

Evaluating leading companies in the EU5 rheumatoid arthritis sector

  • Abbvie
  • Biogen
  • Bristol-Myers Squibb
  • Eli Lilly
  • Merck Sharp & Dohme
  • Pfizer
  • Roche
  • Sanofi
  • UCB

Leading brands covered in this report

  • Benepali (etanercept; Biogen)
  • Cimzia (certolizumab pegol; UCB)
  • Enbrel (etanercept; Pfizer)
  • Humira (adalimumab; AbbVie)
  • Kevzara (sarilumab; Sanofi)
  • MabThera (rituximab; Roche)
  • Olumiant (baricitinib, Eli Lilly)
  • Orencia (abatacept; Bristol-Myers Squibb)
  • Remicade (infliximab; Merck Sharp & Dohme)
  • RoActemra (tocilizumab; Roche)
  • Simponi (golimumab; Merck Sharp & Dohme)
  • Xeljanz (tofacitinib; Pfizer)

Answering important market access questions

  • What underpins the physicians’ prescribing of Humira, RoActemra and Orencia?
  • What is the overall impact of market barriers on prescribing?
  • Not available on formulary? Not recommended in guidelines? Limited availability? What market access obstacles are impacting RoActemra, Simponi and Xeljanz?
  • How many market barriers are impacting MabThera, RoActemra and Kevzara?
  • How are market access issues impacting the market shares of Benepali, Cimzia and Enbrel and which competitor brands are benefitting?

Market access barriers examined in this survey

  • Not available on formulary
  • Too expensive
  • Not recommended by guidelines
  • Limited availability
  • Patients prefer other medications
  • Only recommended for certain patient types
  • Is not reimbursable

Exclusive to FirstView, Market Access Impact surveys reveal the barriers that influence prescribing, identify the brands that win or lose market share, and highlight the
brand-specific market access challenges that management must overcome

The experience of the physicians surveyed

This detailed analysis is based on a survey of 150 EU5 rheumatologists with a wealth of experience treating rheumatoid arthritis. On average they:

  • Saw 80 patients the month preceding the survey
  • Have 18 years in practice
  • Have prescribed at least one of the brands assessed

This report gives you...

  • Practical data to understand how market barriers impact the prescribing decisions rheumatologists treating rheumatoid arthritis make
  • 31 clear, easy-to-read, charts that provide at-a-glance understanding of the survey findings
  • Actionable and detailed information identifying specific areas where medical access teams can improve brand share

Why FirstView has an edge in pharmaceutical market research

FirstView research draws on LiMA (Leaders in Medicine Atlas), the world's largest directory of 3.5 million vetted and verified physicians. This proprietary physician research platform uses advanced big data capture, processing and analytics powered by AI and machine learning to ensure the most robust samples are used for every FirstView survey.

Buy Now

Buy and Download this report

Other RHEUMATOID ARTHRITIS reports available

Market Access Impact (US): Rheumatoid Arthritis

Medical Affairs Reputations (US): Rheumatoid Arthritis

Medical Affairs Reputations (EU5): Rheumatoid Arthritis

NPS+ US: Rheumatoid Arthritis

NPS+ Europe: Rheumatoid Arthritis 

KOL Insights: Rheumatoid Arthritis

To learn about our cost effective Rheumatoid Arthritis intelligence package of all reports, please contact us at info@fwreports.com




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved